The Latest Breaking News from Moderna

‘A tremendous step backward, the politicization of science, and RFK Jr., who has been a lifelong anti-vaccine propagandist and science denialist, is now making policy,’ one doctor said

Scientists fear decision may increase vaccine hesitancy, but other countries are still willing to invest in research

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so again.

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stall

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.